Buclizine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C28H33ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0C94V6X681, chemically known as piperazine, 1-(p-tert-butylbenzyl)-4-(p-chloro-.alpha.-phenylbenzyl)-, dihydrochloride but generally known as buclizine, which bears US NIH Compound Identifier 6729. Buclizine most often comes in base, dihydrochloride, and hydrochloride forms. European Medicines Agency schedules Buclizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05947MIG. The term BUCLIZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules buclizine in its Anatomical Therapeutic Chemical (ATC) Classification. BUCLIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule buclizine under HS 29335995 and SITC 51576. As of Q4 2014, BUCLIZINE remains the US FDA Preferred Term for this commodity. Buclizine bears US NLM identifiers UMLS ID C0164386 and NCI Concept Code C65273. SMILES: CLC1CCC(C(N2CCN(CC2)CC2CCC(C(C)(C)C)CC2)C2CCCCC2)CC1.